The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report

Detalhes bibliográficos
Autor(a) principal: Marques Soares Valente, Patricia
Data de Publicação: 2019
Outros Autores: Claudino Pires de Souza, Walter, Pinho Braga, Eduardo, Ferreira Neves, Thamires, Lopes da Silva, Thamires, de Andrade Martins, Wolney, Rodrigues de Castilho, Selma
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/570
Resumo: Introduction: Breast cancer represents the most common neoplasm among women, with elevated morbimortality. With the appearance of new drugs, there has been an increase of global survival; however, trastuzumab, a monoclonal antibody used in the treatment, may promote cardiotoxicity that should be evaluated and monitored during treatment. The aim of this article is to describe a case report of a patient presenting trastuzumab-associated cardiotoxicity and the importance of monitoring and early identification of cardiotoxicity through echocardiography (ECHO). Case report: A 63-year-old female patient, hypertensive, obese, with breast cancer, presented trastuzumab-associated cardiotoxicity, reduced left ventricular ejection fraction (LVEF), who developed diabetes after the treatment. The patient underwent regular echocardiography follow-up during treatment and this process was essential for early detection and appropriate management of trastuzumab-associated cardiotoxicity. An algorithm was used to determine the causality. Conclusion: This study shows the importance of LVEF follow-up with ECHO in patients undergoing cardiotoxic chemotherapy, and the monitoring of possible metabolic changes after oncologic treatment.
id INCA-1_8b5a834e6053d00ca5d925fb35ec69d3
oai_identifier_str oai:rbc.inca.gov.br:article/570
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case ReportLa Importancia del Monitoreo y de la Identificación Temprano de la Cardiotoxicidad del Tratamiento con Trastuzumab en el Cáncer de Mama: Informe de CasoA Importância do Monitoramento e da Identificação Precoce de Cardiotoxicidade do Tratamento com Trastuzumabe no Câncer de Mama: Relato de CasoCardiotoxicidadeNeoplasias da MamaTrastuzumabTratamento FarmacológicoCardiotoxicityBreast NeoplasmsTrastuzumabDrug TherapyCardiotoxicidadNeoplasias de la MamaTrastuzumabTratamiento FarmacológicoIntroduction: Breast cancer represents the most common neoplasm among women, with elevated morbimortality. With the appearance of new drugs, there has been an increase of global survival; however, trastuzumab, a monoclonal antibody used in the treatment, may promote cardiotoxicity that should be evaluated and monitored during treatment. The aim of this article is to describe a case report of a patient presenting trastuzumab-associated cardiotoxicity and the importance of monitoring and early identification of cardiotoxicity through echocardiography (ECHO). Case report: A 63-year-old female patient, hypertensive, obese, with breast cancer, presented trastuzumab-associated cardiotoxicity, reduced left ventricular ejection fraction (LVEF), who developed diabetes after the treatment. The patient underwent regular echocardiography follow-up during treatment and this process was essential for early detection and appropriate management of trastuzumab-associated cardiotoxicity. An algorithm was used to determine the causality. Conclusion: This study shows the importance of LVEF follow-up with ECHO in patients undergoing cardiotoxic chemotherapy, and the monitoring of possible metabolic changes after oncologic treatment.Introducción: El cáncer de mama representa el cáncer más común entre las mujeres, con alta morbilidad y mortalidad. Con el advenimiento de nuevos medicamentos, ha habido un aumento en la supervivencia general, sin embargo, trastuzumab, un anticuerpo monoclonal utilizado en el tratamiento, puede promover la cardiotoxicidad, que debe evaluarse y monitorearse durante el tratamiento. El objetivo de este trabajo es describir un informe de caso de un paciente que presenta cardiotoxicidad asociada con el uso de trastuzumab y la importancia del monitoreo y la identificación temprana de la cardiotoxicidad a través del monitoreo ecocardiográfico (ECHO). Relato del caso: Una paciente de 63 años, hipertensa, obesa, con cáncer de mama, tenía cardiotoxicidad asociada con trastuzumab, fracción de eyección ventricular izquierda (FEVI) reducida y diabetes después del tratamiento. El paciente se sometió a un seguimiento ecocardiográfico regular durante el tratamiento y fue el proceso fundamental para la detección temprana y el manejo adecuado de la cardiotoxicidad asociada con el uso de trastuzumab. Se utilizó un algoritmo para determinar la causalidad. Conclusión: Este estudio muestra la importancia del seguimiento ECHO de la FEVI en pacientes sometidos a quimioterapia cardiotóxica, y el monitoreo de posibles cambios metabólicos después del tratamiento del cáncer.Introdução: O câncer de mama representa a neoplasia mais frequente entre as mulheres, com elevada morbimortalidade. Com o advento de novos medicamentos, houve um aumento na sobrevida global; entretanto, o trastuzumabe, um anticorpo monoclonal utilizado no tratamento, pode promover cardiotoxicidade, que deve ser avaliada e monitorada durante o tratamento. O objetivo deste artigo é descrever um relato de caso de paciente que apresentou cardiotoxicidade associada ao uso de trastuzumabe e a importância do monitoramento e da identificação precoce da cardiotoxicidade por meio do monitoramento pelo ecocardiograma (ECO). Relato do caso: Paciente, sexo feminino, 63 anos, hipertensa, obesa, com câncer de mama, apresentou cardiotoxicidade associada ao uso de trastuzumabe, com redução da fração de ejeção do ventrículo esquerdo (FEVE) e desenvolveu diabetes após o tratamento. A paciente fez acompanhamento regular pelo ECO durante o tratamento, tendo sido esse processo fundamental para a detecção precoce e o manejo adequado da cardiotoxicidade associada ao uso do trastuzumabe. Foi utilizado um algoritmo na determinação da causalidade. Conclusão: Este estudo mostra a importância do acompanhamento da FEVE pelo ECO em pacientes submetidas à quimioterapia cardiotóxica, e do monitoramento de possíveis alterações metabólicas após o tratamento oncológico.INCA2019-12-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRelato de Casoapplication/pdfapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/57010.32635/2176-9745.RBC.2019v65n3.570Revista Brasileira de Cancerologia; Vol. 65 No. 3 (2019): July/Aug./Sept.; e-10570Revista Brasileira de Cancerologia; Vol. 65 Núm. 3 (2019): jul./agosto/sept.; e-10570Revista Brasileira de Cancerologia; v. 65 n. 3 (2019): jul./ago./set.; e-105702176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporenghttps://rbc.inca.gov.br/index.php/revista/article/view/570/494https://rbc.inca.gov.br/index.php/revista/article/view/570/611Copyright (c) 2019 Revista Brasileira de Cancerologiainfo:eu-repo/semantics/openAccessMarques Soares Valente, PatriciaClaudino Pires de Souza, WalterPinho Braga, Eduardo Ferreira Neves, ThamiresLopes da Silva, Thamiresde Andrade Martins, WolneyRodrigues de Castilho, Selma2021-11-29T20:03:33Zoai:rbc.inca.gov.br:article/570Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:03:33Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report
La Importancia del Monitoreo y de la Identificación Temprano de la Cardiotoxicidad del Tratamiento con Trastuzumab en el Cáncer de Mama: Informe de Caso
A Importância do Monitoramento e da Identificação Precoce de Cardiotoxicidade do Tratamento com Trastuzumabe no Câncer de Mama: Relato de Caso
title The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report
spellingShingle The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report
Marques Soares Valente, Patricia
Cardiotoxicidade
Neoplasias da Mama
Trastuzumab
Tratamento Farmacológico
Cardiotoxicity
Breast Neoplasms
Trastuzumab
Drug Therapy
Cardiotoxicidad
Neoplasias de la Mama
Trastuzumab
Tratamiento Farmacológico
title_short The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report
title_full The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report
title_fullStr The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report
title_full_unstemmed The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report
title_sort The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report
author Marques Soares Valente, Patricia
author_facet Marques Soares Valente, Patricia
Claudino Pires de Souza, Walter
Pinho Braga, Eduardo
Ferreira Neves, Thamires
Lopes da Silva, Thamires
de Andrade Martins, Wolney
Rodrigues de Castilho, Selma
author_role author
author2 Claudino Pires de Souza, Walter
Pinho Braga, Eduardo
Ferreira Neves, Thamires
Lopes da Silva, Thamires
de Andrade Martins, Wolney
Rodrigues de Castilho, Selma
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Marques Soares Valente, Patricia
Claudino Pires de Souza, Walter
Pinho Braga, Eduardo
Ferreira Neves, Thamires
Lopes da Silva, Thamires
de Andrade Martins, Wolney
Rodrigues de Castilho, Selma
dc.subject.por.fl_str_mv Cardiotoxicidade
Neoplasias da Mama
Trastuzumab
Tratamento Farmacológico
Cardiotoxicity
Breast Neoplasms
Trastuzumab
Drug Therapy
Cardiotoxicidad
Neoplasias de la Mama
Trastuzumab
Tratamiento Farmacológico
topic Cardiotoxicidade
Neoplasias da Mama
Trastuzumab
Tratamento Farmacológico
Cardiotoxicity
Breast Neoplasms
Trastuzumab
Drug Therapy
Cardiotoxicidad
Neoplasias de la Mama
Trastuzumab
Tratamiento Farmacológico
description Introduction: Breast cancer represents the most common neoplasm among women, with elevated morbimortality. With the appearance of new drugs, there has been an increase of global survival; however, trastuzumab, a monoclonal antibody used in the treatment, may promote cardiotoxicity that should be evaluated and monitored during treatment. The aim of this article is to describe a case report of a patient presenting trastuzumab-associated cardiotoxicity and the importance of monitoring and early identification of cardiotoxicity through echocardiography (ECHO). Case report: A 63-year-old female patient, hypertensive, obese, with breast cancer, presented trastuzumab-associated cardiotoxicity, reduced left ventricular ejection fraction (LVEF), who developed diabetes after the treatment. The patient underwent regular echocardiography follow-up during treatment and this process was essential for early detection and appropriate management of trastuzumab-associated cardiotoxicity. An algorithm was used to determine the causality. Conclusion: This study shows the importance of LVEF follow-up with ECHO in patients undergoing cardiotoxic chemotherapy, and the monitoring of possible metabolic changes after oncologic treatment.
publishDate 2019
dc.date.none.fl_str_mv 2019-12-12
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Relato de Caso
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/570
10.32635/2176-9745.RBC.2019v65n3.570
url https://rbc.inca.gov.br/index.php/revista/article/view/570
identifier_str_mv 10.32635/2176-9745.RBC.2019v65n3.570
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/570/494
https://rbc.inca.gov.br/index.php/revista/article/view/570/611
dc.rights.driver.fl_str_mv Copyright (c) 2019 Revista Brasileira de Cancerologia
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2019 Revista Brasileira de Cancerologia
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 65 No. 3 (2019): July/Aug./Sept.; e-10570
Revista Brasileira de Cancerologia; Vol. 65 Núm. 3 (2019): jul./agosto/sept.; e-10570
Revista Brasileira de Cancerologia; v. 65 n. 3 (2019): jul./ago./set.; e-10570
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042244555898880

Registros relacionados